Household members were contacted by telephone and provided consent forms via E-mail electronic signatures. Randomization was 2:1 to HCQ 200 mg BID or observation for 10 days with total follow-up of 14 days. COVID status was determined by home saliva PCR assay on days 1 and 14. Study drug was shipped to participants. Data of daily symptoms and 6-lead ECGs using a smartphone KardiaMobile® 6L application were collected.
organizing an entirely no in-person contact clinical trial is feasible during a 22 COVID-19 pandemic 23~Remote smartphone 6-lead ECG monitoring is possible even in a group unfamiliar 24 with the technology 25~Hydroxychloroquine used prophylactically at 200 mg BID had no observable 26 cardiotoxicity 27~Additional study using this technique is warranted to look at reliability and cost-28 effectiveness